Patents Examined by Marcia S. Noble
  • Patent number: 10893667
    Abstract: Methods, uses, and compositions for manipulating genomic DNA. Some of the embodiments of the invention provide for making a founder animal that is completely free of all unplanned genetic modifications. Some embodiments are directed to removing genetic faults in established breeds without making other alterations to the genome. Other embodiments are directed to particular tools or processes such as TALENs or CRISPR with a preferred truncation. One embodiment involves introducing a targeted targeting endonuclease system and a HDR template into a cell (optionally with a mismatch in the binding of the targeting endonuclease and the targeted site). Another embodiment includes processes of making a genetically modified livestock animal comprising a genome that comprises inactivation of a neuroendocrine gene selective for sexual maturation, with the inactivation of the gene preventing the animal from becoming sexually mature.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: January 19, 2021
    Assignee: Recombinetics, Inc.
    Inventors: Scott C. Fahrenkrug, Daniel F. Carlson
  • Patent number: 10894086
    Abstract: The present invention relates to a functional hydrated hyaluronic acid and a method for producing 5th generation coated lactic acid bacteria having excellent intestinal mucoadhesive ability and a selective antagonism using the same and, more specifically, to a functional hydrated hyaluronic acid in which components fermented by lactic acid bacteria are captured in hyaluronic acid, which is a natural polymer substance, and a method for producing coated lactic acid bacteria using the same. The quadruply coated lactic acid bacteria coated using the functional hydrated hyaluronic acid according to the present invention is quadruply coated with a water-soluble polymer, a functional hydrated hyaluronic acid, a coating agent having porous particles, and a protein, thereby producing an excellent intestinal mucoadhesive ability, exhibiting an antibacterial action against deleterious bacteria in the intestines, and promoting growth of beneficial bacteria in the intestines.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: January 19, 2021
    Assignee: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Seung-Hun Lee, Dae Jung Kang, Jae-Hoon Kang
  • Patent number: 10874748
    Abstract: Methods for treating tendinopathy and tendonitis and for preventing tendinopathy are disclosed.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 29, 2020
    Assignees: Albert Einstein College of Medicine, Icahn School of Medicine at Mount Sinai, Montefiore Medical Center
    Inventors: Hui B. Sun, Evan L. Flatow, Tony Wanich, Konrad Gruson, Nelly Andarawis-Puri
  • Patent number: 10876096
    Abstract: Cell culture compositions containing LFM-A13 or a structurally related compound can enhance global hepatic function. For example, LFM-A13 is shown to enhance levels of a broad variety of drug metabolism enzymes, including CYP enzymes, and other hepatic enzymes. LFM-A13 is also shown to promote differentiation of stem cells into hepatocytes. LFM-A13 and structurally related compounds can be used in cell culture to enhance global drug metabolism of liver cells for enhanced in vitro study the effects of drug metabolism on other candidate drug compounds.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: December 29, 2020
    Assignee: Corning Incorporated
    Inventors: Ronald Allen Faris, Yulong Hong, Joydeep Lahiri, Jin Liu, Olivia Grace Weeks
  • Patent number: 10874092
    Abstract: Described herein is a method for producing a chimeric non-human animal expressing a human a MYF5, MYOD, MRF4 gene or a combination thereof gene comprising: a) generating an MYF5, MYOD, MRF4 or combination thereof null non-human animal cell, wherein both copies of the non-human MYF5, MYOD, MRF4 gene or combination thereof carry a mutation that prevents production of functional MYF5, MYOD, MRF4 protein or combination thereof in said non-human animal; b) creating a MYF5, MYOD, MRF4 or combination thereof null non-human blastocyst by somatic cell nuclear transfer comprising fusing a nucleus from said MYF5, MYOD, MRF4 or combination thereof null non-human animal cell of a) into an enucleated non-human oocyte and activating said oocyte to divide so as to form an MYF5, MYOD, MRF4 or combination thereof null non-human blastocyst; c) introducing human stem cells into the MYF5, MYOD, MRF4 or combination null non-human blastocyst of b); and d) implanting said blastocyst from c) into a pseudopregnant surrogate non-human
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: December 29, 2020
    Assignee: Regents of the University of Minnesota
    Inventors: Daniel J. Garry, Mary G. Garry, Naoko Koyano
  • Patent number: 10865381
    Abstract: The present disclosure generally regards methods and compositions for providing multi-lineage hematopoietic precursor cells from pluripotent stem cells (PSCs). The PSCs comprise an expression construct encoding an ETS/ERG gene, GATA2 and HOXA9. Also provided are methods for providing hematopoietic stem cells capable of long-term engraftment in mammals, such as humans. Further provided are therapeutic compositions including the provided hematopoietic stem cells and precursors of hematopoietic cells, and methods of using such for the treatment of subjects.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: December 15, 2020
    Assignee: FUJIFILM Cellular Dynamics, Inc.
    Inventors: Junying Yu, Maksym A. Vodyanyk, Jeffrey Sasaki, Deepika Rajesh, Sarah A. Burton
  • Patent number: 10857185
    Abstract: Cocktails of chemical inducers of neuron-like properties (CINP) is provided, which includes cAMP agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, TGF? receptor inhibitors, and BET family bromodomain inhibitors and optionally, a selective inhibitor of ROCK or p38 MAPK. These cocktails are used in a method of inducing neuron-like properties in partially or completely differentiated non-neuronal cells. The method includes contacting cells of a first type (non-neuronal) with the CINPs for a sufficient period of time to result in reprogramming the cell into cells of a second type having neuron-like characteristics (CiNs). Isolated chemically induced neurons (CiNs) can be used in a number of applications, including but not limited to cell therapy.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: December 8, 2020
    Assignees: Beihao Stem Cell and Regenerative Medicine Research Institutes Co., Ltd., Peking University
    Inventors: Hongkui Deng, Xiang Li, Xiaohan Zuo
  • Patent number: 10857239
    Abstract: The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 8, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Hawa Camara
  • Patent number: 10844356
    Abstract: The invention provides cell culture conditions for culturing stem cells, including feeder-free conditions for generating and culturing human induced pluripotent stem cells (iPSCs). More particularly, the invention provides a culture platform that allows long-term culture of pluripotent cells in a feeder-free environment; reprogramming of cells in a feeder-free environment; single-cell dissociation of pluripotent cells; cell sorting of pluripotent cells; maintenance of an undifferentiated status; improved efficiency of reprogramming; and generation of a naïve pluripotent cell.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: November 24, 2020
    Assignee: FATE THERAPEUTICS, INC.
    Inventors: Bahram Valamehr, Ramzey Abujarour, Peter Flynn
  • Patent number: 10836997
    Abstract: Provided is a method of differentiating a pluripotent stem cell of mammalian origin into a desired cell type by predicting the direction of cell differentiation to be caused by induction of expression of a transcription factor. A human gene expression correlation matrix using human cells has been newly created, and further, it has been confirmed that human pluripotent stem cells can be differentiated into a desired cell type by introducing, into the human pluripotent stem cells, a transcription factor cocktail selected from the matrix.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: November 17, 2020
    Assignee: KEIO UNIVERSITY
    Inventor: Minoru Ko
  • Patent number: 10834908
    Abstract: Disclosed is a non-human animal comprising a genetic construct expressing TCR? and TCR? genes and wherein the animal comprises a null-mutated Rag-2 locus. Described herein is also a NOD.Rag2?/? mouse expressing a transgenic ?,? T cell receptor. The animals spontaneously develop chronic inflammation and fibrosis, and are useful as animal models of fibrotic disease.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: November 17, 2020
    Assignee: INFICURE BIO AB
    Inventor: Dan Holmberg
  • Patent number: 10829738
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: November 10, 2020
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10822394
    Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: November 3, 2020
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt
  • Patent number: 10801013
    Abstract: Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: October 13, 2020
    Assignee: NantKwest, Inc.
    Inventors: Hans Klingemann, Laurent Boissel, Patrick Soon-Shiong
  • Patent number: 10787681
    Abstract: The present invention provides humanized viral vectors and methods of use thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. Humanized viral vectors are modified from known viral vectors such as those based on AAV by coating their surface with a human protein such as human serum albumin and optionally a lipid coating or formulation, so that the foreign or non-human nature of the vector is masked. The coating is performed in a manner that reduces or prevents binding of antibodies to the vector surface, thereby reducing or preventing antibody-mediated clearance of vector, but still allowing the vector to transduce target cells and achieve therapeutic gene transfer. Such humanized vectors therefore evade pre-existing immune surveillance, reduce immune responses, and achieve therapeutic gene transfer in the presence of pre-existing antibodies to the viral vector.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: September 29, 2020
    Assignee: The Children's Hospital of Philadelphia
    Inventor: John Fraser Wright
  • Patent number: 10774310
    Abstract: Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: September 15, 2020
    Assignee: NantKwest, Inc.
    Inventors: Hans Klingemann, Laurent Boissel, Patrick Soon-Shiong
  • Patent number: 10752881
    Abstract: The present invention comprises methods and compositions related to trans-differentiating differentiated cells, the methods comprising bringing said cells into contact with a polypeptide or a nucleic acid encoding said polypeptide.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: August 25, 2020
    Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH)
    Inventors: Sergio Gascón Jiménez, Magdalena Götz
  • Patent number: 10745670
    Abstract: A culture medium is provided which is capable of establishing expanded potential stem cell (EPSC) lines which resemble naive or ground state ES cells, but are also able to differentiate into placenta trophoblasts and the embryo proper. Methods are provided using the medium for the in vitro conversion and maintenance of cells, including pluripotent cells into EPSCs.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: August 18, 2020
    Assignee: GENOME RESEARCH LIMITED
    Inventors: Pentao Liu, David Ryan, Xuefei Gao, Wei Wang, Jian Yang
  • Patent number: 10729112
    Abstract: The present invention relates to a transgenic pig comprising a mutated IAPP gene and displaying a phenotype associated with diabetes. The invention also relates to a transgenic blastocyst, embryo, fetus, donor cell and/or cell nucleus derived from said transgenic pig. The invention further relates to use of the transgenic pig as a model system for studying therapy, treatment and/or prevention of diabetes.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: August 4, 2020
    Assignee: Aarhus Universitet
    Inventors: Lars Bolund, Yonglun Luo
  • Patent number: 10723998
    Abstract: Disclosed is a use of ethyl p-methoxycinnamate and derivatives thereof in preparing drugs, culture media, regulating agents or cosmetic and skin caring products for maintaining self-renewal and pluripotency of stem cells. The stem cells comprise adult stem cells, embryonic stem cells and induced pluripotent stem (iPS) cells. Also disclosed is a use of ethyl p-methoxycinnamate and the derivatives thereof in in-vitro amplification of stem cells and preparation of induced pluripotent stem (iPS) cells and a use of ethyl p-methoxycinnamate and the derivatives thereof in preparing drugs for treating cell deletion or injury diseases.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: July 28, 2020
    Assignee: Northeast Normal University
    Inventors: Yongli Bao, Yuxin Li, Hongshuang Qin